Celltrion starts global Phase 3 clinical trials on Remsima’s SC type

In order to secure competitiveness in the TNF-α inhibitor(autoimmune disease therapy) market, Celltrion will start the global Phase 3 clinical trial of the Remsima’s SC type(subcutaneous injection) as a two-track strategy on Remsima.

The Remsima’s safety and pharmacokinetics were already proven in Phase 1 clinical trials in Korea, and the application of its Phase 3 clinical trials was turned i...